Menopause Hormone Therapy: Questions to Ask Before Deciding

One friend says hormones changed her life. Another says she would never take them. Meanwhile, you are trying to get through a workday after another sweaty, interrupted night. It is reasonable to want a clearer answer than either “everyone should take them” or “they are always dangerous.”

Menopause hormone therapy can help certain symptoms, but the decision depends on what is bothering you, your health history, the treatment type, and your preferences. Menopause is a life transition—not a disease you need to cure. You also do not have to accept symptoms that are disrupting your life without asking about care.

At besa Health, we want people in Santa Ana and Orange County to feel prepared for that conversation. A primary-care visit can be a starting point for discussing symptoms and the next appropriate step. This guide is about making an informed decision, not choosing a prescription for yourself.

1. What exactly are we trying to treat?

Start with the change you most want: fewer hot flashes during meetings, less discomfort with intimacy, or fewer nights interrupted by sweating. “I want to feel like myself” matters, too—but giving it a practical example helps you and your clinician judge whether a plan is working.

According to ACOG’s hormone therapy guidance, systemic estrogen is the most effective treatment for hot flashes and night sweats. Hormone treatment can also address vaginal dryness, depending on the formulation. That does not make it the answer to every symptom that happens in midlife.

Fatigue, mood changes, or poor sleep deserve an individual assessment rather than an automatic hormone explanation. Our guide to perimenopause and stress explores that overlap. If sleep is your main concern, the menopause sleep visit guide can help you describe the pattern.

2. Is the treatment systemic or local?

“Hormone therapy” describes more than one approach. Ask which one is being discussed before comparing a friend’s experience with your own.

The FDA explains the different treatment forms. Systemic therapy reaches the body through the bloodstream; examples include pills, patches, gels, and sprays. Low-dose vaginal therapy targets vaginal symptoms such as dryness and painful sex, with much less hormone entering circulation. It is not the same treatment as systemic therapy for hot flashes. Not every vaginal product has the same purpose, so ask about the specific product.

If you have a uterus and use systemic estrogen, protection of the uterine lining is important. This usually involves a progestogen; another option pairs certain estrogen with bazedoxifene. The Office on Women’s Health treatment overview explains these distinctions. Ask whether uterine protection is needed with the exact regimen being considered—not whether everyone needs the same combination.

3. How does my history change the balance?

Age and timing matter, but they are not a permission slip. The Menopause Society describes a generally more favorable benefit-risk balance for appropriate candidates younger than 60 or within 10 years of menopause. Your individual history still needs review. Starting later requires a different discussion, not assumptions based on a birthday alone.

Bring up any history of blood clots, stroke, heart attack, liver problems, unexplained vaginal bleeding, or breast or uterine cancer. These can make systemic treatment inappropriate or require specialized assessment. The FDA’s medication guide lists important restrictions and risks by treatment type. If you have had breast cancer, involve your cancer care team before using hormone therapy, including vaginal estrogen.

A useful question is: “Which part of my history changes your recommendation, and how?” If a patch is suggested instead of a pill, ask why that route fits you. A different route can change the risk discussion; it does not make a medication risk-free.

4. What do the newer FDA warning changes mean?

You may have seen headlines suggesting the warnings disappeared. On February 12, 2026, the FDA announced approved labeling changes for an initial six menopausal hormone therapy products. Those changes removed certain cardiovascular, breast cancer, and probable dementia statements from boxed warnings. That was not an announcement that every product is safe for every person.

The Office on Women’s Health safety update explains that relevant risks remain elsewhere in prescribing information; the endometrial cancer boxed warning remains for systemic estrogen-alone products. Ask your clinician to review the current label for the actual medication under consideration. A headline cannot substitute for that conversation.

5. What if I prefer not to use hormones?

That is a valid preference, and it should lead to a discussion of alternatives—not an end to the conversation. Nonhormonal prescription options can help hot flashes. For vaginal dryness, ask whether a moisturizer or lubricant is appropriate and when additional treatment should be considered. Options address different problems and have their own limitations.

The Office on Women’s Health outlines hormone and nonhormone approaches. Ask what benefit to expect, what monitoring a medicine needs, and what happens if it does not help enough. Nonhormonal does not automatically mean no side effects.

If anxiety or low mood is part of what you are experiencing, it deserves attention in its own right. You can learn about mental-health care at besa while discussing your overall care needs. Hormone decisions should not crowd out other concerns that matter to you.

6. Is “bioidentical” the same as FDA-approved?

No. “Bioidentical” can describe hormones in FDA-approved products as well as custom-compounded preparations. ACOG recommends FDA-approved menopausal hormone therapies over routinely using compounded versions when approved formulations exist. Compounded preparations are not FDA-approved, and evidence does not establish that they are safer or more effective.

Before paying for a product described as “natural” or “personalized,” ask its exact name, whether it is FDA-approved, and why it is being recommended. Those are reasonable questions, not a challenge to the clinician.

Your decision checklist: leave with a plan, not just a prescription 📝

Clarify the goal: Which symptom are we targeting first? What improvement would count as meaningful, and what is unlikely to change?

Compare the choices: Why this treatment and route rather than another hormone or nonhormone option? Which risks apply to me?

Make it workable: What will the medication and follow-up cost? Is there a covered alternative? Who can answer questions if the pharmacy cannot fill it? Coverage and availability should be checked, not assumed.

Agree on follow-up: When will we reassess benefits and side effects? Who should I contact about unexpected bleeding or another concern? What would make us revisit the plan?

You can also say, “I would like time to think.” Bring a trusted person if you want support, while keeping your own priorities at the center. Do not start, stop, or change prescribed hormones based on a friend’s regimen or an online article.

Symptoms that should not wait for the next routine visit

Report unusual vaginal bleeding promptly, including bleeding after menopause, rather than assuming it is an expected treatment effect. Seek emergency care for sudden chest pain, shortness of breath, one-sided weakness, or trouble speaking. MedlinePlus lists serious symptoms associated with estrogen-progestin therapy. These symptoms need urgent attention whether or not you use hormones.

Start the conversation in Santa Ana

You do not need to arrive with a medication selected. Start with your symptoms, your questions, and what you want daily life to feel like. Review ways to get care with besa and contact us about an appropriate primary-care evaluation. Ask about appointment availability, insurance or payment arrangements, and whether a specific treatment requires referral; this article does not promise hormone prescribing or specialty services.

Ready to take that next step? Request an appointment or visit the besa app page for scheduling and care-communication options. We can begin with a conversation—not a decision you have to make alone.

Educational information, not individualized medical advice. Sources checked November 2, 2026. Treatment decisions require an assessment with your own clinician.